Emerging infections in burns

Surgical Infections

Volumn 10, Issue 5, 2009, Pages 389-397

  Branski, Ludwik K ^a   Al Mousawi, Ahmed ^a   Rivero, Haidy ^a   Jeschke, Marc G ^a   Sanford, Arthur P ^a   Herndon, David N ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; DALBAVANCIN; DALFOPRISTIN; DAPTOMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; STREPTOGRAMIN DERIVATIVE; TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; VORICONAZOLE;

ACINETOBACTER; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; ASPERGILLOSIS; ASPERGILLUS; BODY SURFACE; BURN INFECTION; CANDIDA; DIAGNOSTIC ACCURACY; DRUG EFFICACY; FLUID THERAPY; FUSARIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HIGH RISK PATIENT; HUMAN; LENGTH OF STAY; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BURNS; CHILD; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, MICROBIAL; FUNGI; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS;

EID: 72449165904     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2009.024     Document Type: Review

References (70)

1. Herndon DN, Barrow RE. History of treatments of burns. In Herndon DN, ed. Total Burn Care, 3rd edition. Philadelphia: WB Saunders, 2007:1-8.
2. Bull JP, Fisher AJ. A study of mortality in a burns unit: A revised estimate. Ann Surg 1954;139:269-274.
3. Muller MJ, Herndon DN. The challenge of burns. Lancet 1994;343:216-220.
4. Saffle JR, Davis B, Williams P. Recent outcomes in the treatment of burn injury in the United States: A report from the American Burn Association Patient Registry. J Burn Care Rehabil 1995;16:219-232.
5. Baxter CR, Shires T. Physiological response to crystalloid resuscitation of severe burns. Ann NY Acad Sci 1968;150: 874-894.
6. Richards C, Emori TG, Edwards J, et al. Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001;29:400-403.
7. Schwacha MG. Macrophages and post-burn immune dysfunction. Burns 2003;29:1-14.
8. Pruitt BA Jr, McManus AT, Kim SH, et al. Burn wound infections: Current status. World J Surg 1998;22:135-145.
9. Gallagher JJ, Williams-Bouyer N, Villarreal C, et al. Treatment of infection in burns. In Herndon DN, ed. Total Burn Care, 3rd edition. Philadelphia: WB Saunders, 2007:136-176.
10. Greenhalgh DG, Saffle JR, Holmes JHT, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776-790.
11. D'Avignon LC, Saffle JR, Chung KK, et al. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008;64(3 Suppl):S277-S286.
12. Miranda BH, Ali SN, Jeffery SL, et al. Two stage study of wound microorganisms affecting burns and plastic surgery inpatients. J Burn Care Res 2008;29:927-932.
13. Wibbenmeyer LA, Kealey GP, Latenser BA, et al. Emergence of the USA300 strain of methicillin-resistant Staphylococcus aureus in a burn-trauma unit. J Burn Care Res 2008;29:790-797.
14. Durtschi MB, Orgain C, Counts GW, et al. A prospective study of prophylactic penicillin in acutely burned hospitalized patients. J Trauma 1982;22:11-14.
15. de Macedo JL, Santos JB. Bacterial and fungal colonization of burn wounds. Mem Inst Oswaldo Cruz 2005;100:535-539.
16. Cook N. Methicillin-resistant Staphylococcus aureus versus the burn patient. Burns 1998;24:91-98.
17. Phillips LG, Heggers JP, Robson MC. Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil 1992;13:293-297.
18. Robson MC, Krizek TJ, Heggers JP. Biology of surgical infection. In Ravitch MM, ed. Current Problems in Surgery. Chicago: Year Book Medical Publishers, 1973:1-62.
19. Guggenheim M, Zbinden R, Handschin AE, et al. Changes in bacterial isolates from burn wounds and their antibiograms: A 20-year study (1986-2005). Burns 2009;35:553-560.
20. Schuster KM, Wilson D, Schulman CI, et al. Continuousinfusion oxacillin for the treatment of burn wound cellulitis. Surg Infect 2009;10:41-45.
21. de Macedo JL, Rosa SC, Castro C. Sepsis in burned patients. Rev Soc Bras Med Trop 2003;36:647-652.
22. Thabet L, Turki A, Ben Redjeb S, et al. [Bacteriological profile and antibiotic resistance of bacteria isolates in a burn department](Fre). Tunis Med 2008;86:1051-1054.
23. Prasanna M, Thomas C. A profile of methicillin-resistant Staphylococcus aureus infection in the burn center of the Sultanate of Oman. Burns 1998;24:631-636.
24. Barber M, Rozwadowska-Dowzenko M. Infection by penicillinresistant staphylococci. Lancet 1948;2:641-644.
25. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963;1:904-907.
26. Enright MC. The evolution of a resistant pathogen-the case of MRSA. Curr Opin Pharmacol 2003;3:474-479.
27. Metzger R, Bonatti H, Sawyer R. Future trends in the treatment of serious gram-positive infections. Drugs Today 2009;45:33-45.
28. Ben-David D, Mermel LA, Parenteau S. Methicillin-resistant Staphylococcus aureus transmission: The possible importance of unrecognized health care worker carriage. Am J Infect Control 2008;36:93-97.
29. Dansby W, Purdue G, Hunt J, et al. Aerosolization of methicillin- resistant Staphylococcus aureus during an epidemic in a burn intensive care unit. J Burn Care Res 2008;29:331-337.
30. Mayhall CG. The epidemiology of burn wound infections: Then and now. Clin Infect Dis 2003;37:543-550.
31. Hodle AE, Richter KP, Thompson RM. Infection control practices in U.S. burn units. J Burn Care Res 2006;27:142-151.
32. Wang Z, Rong XZ, Zhang T, et al. [Distribution and drug resistance analysis of bacteria in different wound infections](Chi). Nan Fang Yi Ke Da Xue Xue Bao 2009;29:82-83.
33. Zar HJ, Cotton MF. Nosocomial pneumonia in pediatric patients: Practical problems and rational solutions. Paediatr Drugs 2002;4:73-83.
34. Murray PR, Baron EJ, Jorgensen JH, et al. Manual of Clinical Microbiology, 8th edition. Washington, DC: ASM Press, 2003.
35. Shoup M, Weisenberger JM, Wang JL, et al. Mechanisms of neutropenia involving myeloid maturation arrest in burn sepsis. Ann Surg 1998;228:112-122.
36. Walton MA, Villarreal C, Herndon DN, et al. The use of aztreonam as an alternate therapy for multiresistant Pseudomonas aeruginosa. Burns 1997;23:225-227.
37. Japoni A, Alborzi A, Kalani M, et al. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 2006;32:343-347.
38. Ozkurt Z, Ertek M, Erol S, et al. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005;31:870-873.
39. Mokaddas EM, Sanyal SC. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin=tazobactam. J Chemother 1999;11:93-96.
40. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-215.
41. Fass RJ, Barnishan J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother 1995;36:343-353.
42. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gramnegative bacteria. Ann Pharmacother 1999;33:960-967.
43. Li J, Nation RL, Turnidge JD, et al. Colistin: The re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
44. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977;46:723-763.
45. Nord NM, Hoeprich PD. Polymyxin B and colistin: A critical comparison. N Engl J Med 1964;270:1030-1035.
46. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: The major determinant of distribution and persistence in the body. J Infect Dis 1971;124:394-400.
47. Kunin CM, Bugg A. Recovery of tissue bound polymyxin B and colistimethate. Proc Soc Exp Biol Med 1971;137:786-790.
48. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
49. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
50. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991;91:86S-89S.
51. Burchard KW, Minor LB, Slotman GJ, et al. Fungal sepsis in surgical patients. Arch Surg 1983;118:217-221.
52. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-421.
53. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645.
54. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control 2007;35:290-301.
55. Ballard J, Edelman L, Saffle J, et al. Positive fungal cultures in burn patients: A multicenter review. J Burn Care Res 2008;29:213-221.
56. Mousa HA, Al-Bader SM, Hassan DA. Correlation between fungi isolated from burn wounds and burn care units. Burns 1999;25:145-147.
57. Al-Mousawi AM, Jeschke MG, Herndon DN. History of metabolic treatments in burn care. Wounds 2008;20:185-191.
58. Fox CL Jr, Rappole BW, Stanford W. Control of Pseudomonas infection in burns by silver sulfadiazine. Surg Gynecol Obstet 1969;128:1021-1026.
59. Lindberg RB, Moncrief JA, Switzer WE, et al. The successful control of burn wound sepsis. J Trauma 1965;5:601-616.
60. Moyer CA, Brentano L, Gravens DL, et al. Treatment of large human burns with 0.5 per cent silver nitrate solution. Arch Surg 1965;90:812-867.
61. Becker WK, Cioffi WG Jr, McManus AT, et al. Fungal burn wound infection: A 10-year experience. Arch Surg 1991;126: 44-48.
62. Schofield CM, Murray CK, Horvath EE, et al. Correlation of culture with histopathology in fungal burn wound colonization and infection. Burns 2007;33:341-346.
63. Dean DA, Burchard KW. Fungal infection in surgical patients. Am J Surg 1996;171:374-382.
64. Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000;15:83-90.
65. Bochud PY, Bonten M, Marchetti O, et al. Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004;32(11 Suppl): S495-S512.
66. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
67. doctorfungus.org. Available at www.doctorfungus.org= thefungi=index.htm [cited March 12, 2009].
68. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-260.
69. McKinsey DS. Making best use of the newer antifungal agents. Drug Benefit Trends March 2004:131-147.
70. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: A new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001;33:1871-1878.